Collegium Pharmaceutical, Inc. (COLL)
- Previous Close
33.31 - Open
33.26 - Bid 23.58 x 200
- Ask 42.02 x 200
- Day's Range
32.65 - 33.37 - 52 Week Range
20.83 - 40.95 - Volume
96,204 - Avg. Volume
476,947 - Market Cap (intraday)
1.075B - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
13.10 - EPS (TTM)
2.51 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.00
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
www.collegiumpharma.com197
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: COLL
Performance Overview: COLL
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COLL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COLL
Valuation Measures
Market Cap
1.09B
Enterprise Value
1.40B
Trailing P/E
13.28
Forward P/E
5.39
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.56
Price/Book (mrq)
4.91
Enterprise Value/Revenue
2.47
Enterprise Value/EBITDA
3.94
Financial Highlights
Profitability and Income Statement
Profit Margin
16.46%
Return on Assets (ttm)
10.56%
Return on Equity (ttm)
46.43%
Revenue (ttm)
566.92M
Net Income Avi to Common (ttm)
93.29M
Diluted EPS (ttm)
2.51
Balance Sheet and Cash Flow
Total Cash (mrq)
318.05M
Total Debt/Equity (mrq)
283.56%
Levered Free Cash Flow (ttm)
297.07M
Research Analysis: COLL
Company Insights: COLL
COLL does not have Company Insights
Research Reports: COLL
Raising target price to $40.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of BUY; a target price of $40.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating increased to a BUY
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of BUY; a target price of $38.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetLowering target price to $37.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetRaising target price to $41.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target